Blood - ISSN 0006-4971
Source Normalized Impact per Paper (SNIP): 3.215 Source Normalized Impact per Paper (SNIP):
SNIP measures contextual citation impact by weighting citations based on the total number of citations in a subject field.
SCImago Journal Rank (SJR): 5.416 SCImago Journal Rank (SJR):
SJR is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and a qualitative measure of the journal’s impact.
Impact Factor: 17.794 (2019) Impact Factor:
The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
© 2017 Journal Citation Reports ® (Clarivate Analytics, 2017)
5 Year Impact Factor: 14.82 (2019) Five-Year Impact Factor:
To calculate the five year Impact Factor, citations are counted in 2016 to the previous five years and divided by the source items published in the previous five years.
© 2017 Journal Citation Reports ® (Clarivate Analytics, 2017)
Volumes: Volumes 137-138
Issues: 52 issues
ISSN: 00064971
Editor-in-Chief: Berliner

Personal Subscription

Sales tax will be calculated at check-out Price includes VAT/GST

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.


Blood, the official journal of the American Society of Hematology, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate.

Blood welcomes submission of manuscripts reporting on clinical trials whether phase 1, 2, 3 or 4. Reports should include a full description of the study design, patient population, methodology and conduct, and statistical plan.

Immunobiology and Immunotherapy encompass a wide spectrum of research, but Blood can accommodate only papers that have clear and important implications for hematology. Preference is given to papers focusing on human immunobiology, immunotherapy, and immune pharmacology approaches in the human setting and those with significant implications for understanding of normal or malignant hematologic processes. Papers on tumor immunology, tumor vaccines and cancer immunotherapy development may be appropriate if the target cells or antigens are relevant to hematologic malignancies, but generally Blood cannot accommodate tumor immunology papers focusing solely on non-hematologic tumor types.

Papers investigating autoimmunity and utilizing non-hematologic models are not within the scope of Blood.

Vascular biology papers that focus primarily on atherosclerosis are outside the scope of Blood and instead should be considered for alternative journals.

Authors are invited to contact the Editor-in-Chief, Nancy Berliner, MD prior to submission if they are uncertain whether their work falls within the general scope of the journal.